Emerging Growth Conference 93
Logotype for SBC Medical Group Holdings Incorporated

SBC Medical Group Holdings (SBC) Emerging Growth Conference 93 summary

Event summary combining transcript, slides, and related documents.

Logotype for SBC Medical Group Holdings Incorporated

Emerging Growth Conference 93 summary

11 Jun, 2026

Business model and operations

  • Operates as a medical services organization, providing centralized support to clinics across multiple healthcare fields, using an asset-light franchise model due to Japanese regulations.

  • Portfolio includes over 20 brands, covering aesthetic, dermatology, orthopedics, fertility, gynecology, dentistry, alopecia, and ophthalmology, serving 6.7 million customers annually through 284 clinics.

  • Multi-brand strategy enables targeting diverse patient needs and maintaining long-term relationships, with 72% repeat rate and strong customer loyalty.

  • Franchise model features fixed and variable fees, equipment leasing, and procurement revenue, with clinics reaching profitability in 5-6 months.

  • No franchise agreement has ever been terminated in 26 years, highlighting model durability.

Financial performance and resilience

  • Q1 2026 revenue was $43 million, a 9% YoY decline due to fee structure revisions, but underlying revenue grew 11% YoY when adjusted for these changes.

  • Underlying EBITDA increased 17% YoY after adjusting for fee structure revisions.

  • Average revenue per visit rebounded to JPY 316 in Q4 2025, up 11% YoY, following strategic pricing and multi-branding adjustments.

  • Business demonstrated resilience during COVID-19 and benefited from tighter Japanese regulations, strengthening its market position.

  • EBITDA margin exceeds 40%, with net income up 9% YoY to JPY 51 million last year.

Growth strategy and initiatives

  • Four key initiatives: launch of SBC Wellness 2.0 focused on longevity, expansion into non-aesthetic medical fields, disciplined global expansion, and AI-driven operational transformation.

  • SBC Wellness 2.0 targets the $34 billion Japanese longevity market, leveraging corporate B2B channels for scalable growth.

  • Applying proven operational playbook to new fields like AGA, dentistry, orthopedics, fertility, and ophthalmology.

  • Global expansion is selective, with Japan as the core; U.S. growth pursued via partnership with OrangeTwist and further opportunities in Southeast Asia.

  • Goal to increase global business from 1% to 25% of revenue within five years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more